王保军, 韩民, 李志遥, 曹晶, 王根辈, 何毅, 段中余. 水飞蓟宾Mannich碱衍生物的合成及保肝活性研究J. 药学学报, 2018,53(5): 771-777. doi: 10.16438/j.0513-4870.2017-1200
引用本文: 王保军, 韩民, 李志遥, 曹晶, 王根辈, 何毅, 段中余. 水飞蓟宾Mannich碱衍生物的合成及保肝活性研究J. 药学学报, 2018,53(5): 771-777. doi: 10.16438/j.0513-4870.2017-1200
WANG Bao-jun, HAN Min, LI Zhi-yao, CAO Jing, WANG Gen-bei, HE Yi, DUAN Zhong-yu. Synthesis and hepatoprotective activity of Mannich base derivatives of silybinJ. Acta Pharmaceutica Sinica, 2018,53(5): 771-777. doi: 10.16438/j.0513-4870.2017-1200
Citation: WANG Bao-jun, HAN Min, LI Zhi-yao, CAO Jing, WANG Gen-bei, HE Yi, DUAN Zhong-yu. Synthesis and hepatoprotective activity of Mannich base derivatives of silybinJ. Acta Pharmaceutica Sinica, 2018,53(5): 771-777. doi: 10.16438/j.0513-4870.2017-1200

水飞蓟宾Mannich碱衍生物的合成及保肝活性研究

Synthesis and hepatoprotective activity of Mannich base derivatives of silybin

  • 摘要: 本文分别以水飞蓟宾和脱氢水飞蓟宾为先导化合物,首次合成两个水溶性水飞蓟宾Mannich碱衍生物SLB-DEA和DHSLB-PIP,化学结构通过1H NMR和HR-MS进行确证。采用CCl4致小鼠急性肝损伤模型考察两个水飞蓟宾Mannich碱衍生物的抗肝损伤作用,测定肝脏指数变化和血清中谷丙转氨酶(ALT)、谷草转氨酶(AST)、乳酸脱氢酶(LDH)活力及总胆固醇(TC)、甘油三酯(TG)水平,观察肝组织病理组织学变化,并进行大鼠药代动力学研究。研究结果表明,DHSLB-PIP高剂量组(40 mg·kg-1)可以显著降低小鼠ALT、AST、LDH和TG水平,具有量效关系,并且能够改善肝组织的病理学改变。同时SLB-DEA和DHSLB-PIP在大鼠体内的Cmax和AUC0-8 h相对于水飞蓟宾均显著增加,相对生物利用度分别为172.5%和259.8%。本研究设计合成的水飞蓟宾衍生物SLB-DEA和DHSLB-PIP具有良好的水溶性及抗肝损伤生物活性,并且显著提高了水飞蓟宾在大鼠体内的生物利用度,可作为新药候选物进一步研究其成药性。

     

    Abstract: Two novel Mannich base derivatives of silybin, SLB-DEA and DHSLB-PIP, were designed and synthesized. All the structures of new Mannich base derivatives of silybin were characterized by 1H NMR and HR-MS. Their protective action against CCl4-induced liver injury in mice were investigated. The changes of alanine aminotransferase (ALT), aspartate transaminase (AST), lactate dehydrogenase (LDH), total cholesterol (TC) and triglyceride (TG) were determined and the histopathological changes in liver tissues were examined. Pretreatment with a higher dosage of DHSLB-PIP (40 mg·kg-1) prevented CCl4-induced liver injury as indicated by the reduced levels of ALT, AST, LDH and TG. Meanwhile, liver histopathological improvement was observed in the model groups. The pharmacokinetics study in rats showed that the relative bioavailability of SLB-DEA and DHSLB-PIP were 172.5% and 259.8% compared with silybin. All the results suggest that SLB-DEA and DHSLB-PIP may protect liver against injury by CCl4 and the relative bioavailability was significantly increased, which is worth of further investigation for their druggability.

     

/

返回文章
返回